Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Drug Safety
Published in: Drug Safety 8/2011

01-08-2011 | Original Research Article

Metabolic and Neurological Complications of Second-Generation Antipsychotic Use in Children

A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Authors: Dr Tamara Pringsheim, Darren Lam, Heidi Ching, Scott Patten

Published in: Drug Safety | Issue 8/2011

Login to get access

Abstract

Background: Available evidence indicates that the use of antipsychotics, especially second-generation antipsychotics (SGAs), for children with mental health disorders has increased dramatically. Given the demonstrated metabolic and neurological adverse effects seen in adult patients on these medications, detailed evaluation of the risk for these adverse effects in children is appropriate.
Objective: The aim of the study was to assess the evidence for specific metabolic and neurological adverse effects associated with the use of SGAs in children.
Data Sources: MEDLINE (1996–May 2010) and EMBASE (1996–May 2010) databases were searched using highly sensitive search strategies for clinical trials in a paediatric population (children up to age 18 years).
Study Selection: We included any double-blind, randomized controlled trial (RCT) of SGA medications conducted specifically in a paediatric population for the treatment of a mental health disorder. This included the medications risperidone, olanzapine, quetiapine, aripiprazole, clozapine, ziprasidone and paliperidone. The primary outcomes assessed for this review were metabolic and neurological adverse effects, as measured using physical examination manoeuvres, rating scales or laboratory tests. A total of 35 RCTs were included in the analysis, but not all studies had data that could be used in the meta-analysis.
Data Extraction: Abstracts retrieved from the searches were reviewed independently by two different reviewers for potential relevant articles. Full-text articles were then read in detail independently by two different reviewers to see if inclusion criteria were fulfilled. Data were extracted independently by two review authors from included studies and entered onto pre-designed summary forms. Clinical trials were evaluated for methodological quality using quality criteria developed by the US Preventive Services Task Force. Based on the fulfilment of quality criteria, studies were rated as good, fair or poor.
Data Synthesis: Meta-analysis was performed on the data for synthesis, and was carried out for commonly reported outcomes for each medication individually, in comparison with placebo or another drug. Odds ratios (ORs) with 95% confidence intervals for binary outcomes were used. For continuous outcomes, mean differences were used to analyze the data. Meta-analysis revealed that mean weight gain compared with placebo was highest for olanzapine at 3.47 kg (95% CI 2.94, 3.99) followed by risperidone at 1.72kg (95% CI 1.17, 2.26), quetiapine at 1.41kg (95% CI 1.10, 1.81) and aripiprazole at 0.85 kg (95% CI 0.58, 1.13). Olanzapine and clozapine treatment were associated with the highest rate of metabolic laboratory abnormalities in cholesterol and triglycerides. Prolactin elevation occurred with risperidone and olanzapine therapy. Higher odds of extrapyramidal symptoms compared with placebo were seen in children treated with risperidone (OR 3.55; 95% CI 2.04, 5.48) and aripiprazole (OR 3.70; 95% CI 2.37, 5.77). Elevated rates of extrapyramidal symptoms were also experienced with olanzapine use.
Conclusions: There is good evidence to support the existence of both metabolic and neurological adverse effects in children treated with these medications. Proper attention and vigilance to potential metabolic and neurological adverse effects is necessary, and should be considered part of the standard of care.
Appendix
Available only for authorised users
Literature
1.
Leucht S, Pitschel-Walz G, Abraham D, et al. Efficacy and extrapyramidal side effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: a meta-analysis of randomized controlled trials. Schizophr Res 1999; 35: 51–68PubMedCrossRef
2.
Janno S, Holi M, Tuisku K, et al. Prevalence of neuroleptic induced movement disorders in chronic schizophrenia in-patients. Am J Psychiatry 2004; 161: 160–3PubMedCrossRef
3.
DelBello M, Schwiers M, Rosenberg L, et al. A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania. J Am Acad Child Adolesc Psychiatry 2002; 41(10): 1216–23CrossRef
4.
Findling R, Robb A, Nyilas M, et al. A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am J Psychiatry 2008; 11(165): 1369–72
5.
Kryzhanovskaya L, Schulz S, McDougle C, et al. Olanzapine versus placebo in adolescents with schizophrenia: a 6-week randomized, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 2009; 48(1): 60–70PubMedCrossRef
6.
Kumra S, Frazier J, Jacobsen L, et al. Childhood-onset schizophrenia: a double-blind clozapine-haloperidol comparison. Arch Gen Psychiatry 1996; 53(12): 1090–7PubMedCrossRef
7.
Marcus R, Owen R, Kamen L, et al. A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry 2009; 48(11): 1110–9PubMedCrossRef
8.
Sallee F, Kurlan R, Goetz C, et al. Ziprasidone treatment of children and adolescents with tourette’s syndrome: a pilot study. J Am Acad Child Adolesc Psychiatry 2000; 39(3): 292–9PubMedCrossRef
9.
Haas M, Unis A, Armenteros J, et al. A 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia. J Child Adolesc Psychopharmacol 2009; 19(6): 611–21PubMedCrossRef
10.
Patel N, Sanchez R, Johnsrud M, et al. Trends in antipsychotic use in Texas Medicaid population of children and adolescents: 1996 to 2000. J Child Adolesc Psychopharmacol 2002; 12(3): 221–9PubMedCrossRef
11.
Olfson M, Blanco C, Liu L, et al. National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch Gen Psychiatry 2006; 63: 679–85PubMedCrossRef
12.
Newcomer J. Second generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005; 19 Suppl. 1: 1–93PubMedCrossRef
13.
Correll C, Manu P, Olshanskiy V, et al. Cardiometabolic risk of second generation antipsychotic medications during first time use in children and adolescents. JAMA 2009; 302(16): 1765–73PubMedCrossRef
14.
Miller D, Caroff S, Davis S, et al. Extrapyramidal side effects of antipsychotics in a randomized trial. Br J Psychiatry 2008; 193(4): 279–88PubMedCrossRef
15.
Woods SW, Martin A, Spector SG, et al. Effects of development on olanzapine-associated adverse events. J Am Acad Child and Adolesc Psychiatry 2002 Dec; 41(12): 1439–46CrossRef
16.
Harris RP, Helfand MH, Woolf SH, et al. Current methods of the U.S. Preventive Services Task Force. Am J Prev Med 2001; 20 (3 Suppl.): 22–35CrossRef
17.
Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003; 327(7414): 557–60PubMedCrossRef
18.
Research Units on Pediatric Psychopharmacology (RUPP) Autism Network. Risperidone in children with autism and serious behavioural problems. N Engl J Med 2002; 347(5): 314–21CrossRef
19.
Shea S, Turgay A, Carroll A, et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 2004; 114(5): e634–41PubMedCrossRef
20.
Snyder R, Turgay A, Aman M, et al. Effects of risperidone on conduct and disruptive behaviour disorders in children with subaverage IQs. The Risperidone Conduct Study Group. J Am Acad Child Adolesc Psychiatry 2002; 41(9): 1026–36PubMedCrossRef
21.
Aman M, De Smedt G, Derivan A, et al. Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Risperidone Disruptive Behavior Study Group. Am J Psychiatry 2002; 159(8): 1337–46PubMedCrossRef
22.
Van Bellinghen M, De Troch C. Risperidone in the treatment of behavioural disturbances in children and adolescents with borderline intellectual functioning: a double-blind, placebo-controlled pilot trial. J Child Adolesc Psychopharmacol 2001; 11(1): 5–13PubMedCrossRef
23.
Findling R, McNamara N, Branicky L, et al. A double-blind pilot study of risperidone in the treatment of conduct disorder. J Am Acad Child Adolesc Psychiatry 2000; 39(4): 509–16PubMedCrossRef
24.
Buitelaar J, van der Gaag R, Cohen-Kettenis P, et al. A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities. J Clin Psychiatry 2001; 62(4): 239–48PubMedCrossRef
25.
Armenteros J, Lewis J, Davalos M. Risperidone augmentation for treatment-resistant aggression in attention-deficit/ hyperactivity disorder: a placebo-controlled pilot study. J Am Acad Child Adolesc Psychiatry 2007; 26(5): 558–65CrossRef
26.
Haas M, DelBello N, Pandina G, et al. Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, double-blind, placebo-controlled study. Bipolar Disord 2009; 11(7): 687–700PubMedCrossRef
27.
Reyes M, Buitelaar J, Toren P, et al. A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behaviour disorders. Am J Psychiatry 2006; 163(3): 402–10PubMedCrossRef
28.
Sikich L, Hamer R, Bashford R, et al. A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial. Neuropsychopharmacology 2004; 29(1): 133–45PubMedCrossRef
29.
Sikich L, Frazier J, McClellan J, et al. Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizoaffective disorder: findings from the Treatment of Early-Onset Schizophrenia Spectrum disorders (TEOSS) study. Am J Psychiatry 2008; 165(11): 1420–31PubMedCrossRef
30.
Haas M, Eerdekens M, Kushner S, et al. Efficacy, safety and tolerability of two risperidone dosing regiments in adolescent schizophrenia: double-blind study. Br J Psychiatry 2009; 194(2): 158–64PubMedCrossRef
31.
Gilbert D, Batterson J, Sethuraman G, et al. Tic reduction with risperidone versus pimozide in a randomized, double-blind, crossover trial. J Am Acad Child Adolesc Psychiatry 2004; 43(2): 206–14PubMedCrossRef
32.
Gaffney G, Perry P, Lund B, et al. Risperidone versus clonidine in the treatment of children and adolescents with tourette’s syndrome. J Am Acad Child Adolesc Psychiatry 2002; 41(3): 330–6PubMedCrossRef
33.
Nagaraj R, Singhi P, Malhi P. Risperidone in children with autism: randomized, placebo-controlled, double-blind study. J Child Neurol 2006; 21(6): 450–5PubMed
34.
Luby J, Mrakotsky C, Stalets M, et al. Risperidone in preschool children with autistic spectrum disorders: an investigation of safety and efficacy. J Child Adolesc Psychopharmacol 2006; 16(5): 575–87PubMedCrossRef
35.
Miral S, Gencer O, Inal-Emiroglu F, et al. Risperidone versus haloperidol in children and adolescents with AD: a randomized, controlled, double-blind trial. Eur Child Adolesc Psychiatry 2008; 17(1): 1–8PubMedCrossRef
36.
Tohen M, Kryzhanovskaya L, Carlson G, et al. Olanzapine versus placebo in the treatment of adolescents with bipolar mania. Am J Psychiatry 2007; 164(10): 1547–56PubMedCrossRef
37.
Hollander E, Wasserman S, Swanson E, et al. A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive development disorder. J Child Adolesc Psychopharmacol 2006; 16(5): 541–8PubMedCrossRef
38.
DelBello M, Chang K, Welge J, et al. A double-blind, placebo-controlled pilot study of quetiapine for depressed adolescents with bipolar disorder. Bipolar Disord 2009; 11(5): 483–93CrossRef
39.
Connor D, McLaughlin T, Jeffers-Terry M. Randomized controlled pilot study of quetiapine in the treatment of adolescent conduct disorder. J Child Adolesc Psychopharmacol 2008; 18(2): 140–56PubMedCrossRef
40.
DelBello M, Kowatch R, Adler C, et al. A double blind randomized pilot study comparing quetiapine and divalproex for adolescent mania. J Am Acad Child Adolesc Psychiatry 2006; 45(3): 305–13CrossRef
41.
Owen R, Sikich L, Marcus R, et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics 2009; 124(6): 1533–40PubMedCrossRef
42.
Findling R, Nyilas M, Forbes R, et al. Acute treatment of pediatric bipolar I disorder, manic or mixed episode, with aripiprazole: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2009; 70(10): 1441–51PubMedCrossRef
43.
Tramontina S, Zeni C, Ketzer C, et al. Aripiprazole in children and adolescents with bipolar disorder comorbid with attention-deficit/hyperactivity disorder: a pilot randomized clinical trial. J Clin Psychiatry 2009; 70(5): 756–64PubMedCrossRef
44.
Shaw P, Sporn A, Gogtay N, et al. Childhood-onset schizophrenia: a double-blind, randomized clozapine-olanzapine comparison. Arch Gen Psychiatry 2006; 63(7): 721–30PubMedCrossRef
45.
Kumra S, Kranzler H, Gerbino-Rosen G, et al. Clozapine and “high-dose” olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison. Biol Psychiatry 2008; 63(5): 524–9PubMedCrossRef
46.
Mattson N, Ronnemaa T, Juonala M, et al. Childhood predictors of the metabolic syndrome in adulthood: the cardiovascular risk in young finns study. Ann Med 2008; 40: 542–52CrossRef
47.
Al Mamun A, Cramb S, O’Callaghan M, et al. Childhood overweight status predicts diabetes at age 21 years: a follow-up study. Obesity (Silver Spring) 2009; 17(6): 1255–61
48.
Juonala M, Jarvisalo M, Maki-Torkko N, et al. Risk factors identified in childhood and decreased carotid artery elasticity in adulthood. Circulation 2005; 112: 1486–93PubMedCrossRef
49.
Pulkki-Raback L, Elovainio M, Kivimaki M, et al. Depressive symptoms and the metabolic syndrome in childhood and adulthood: a prospective cohort study. Health Psychol 2009; 28(1): 108–16PubMedCrossRef
50.
Morato E, Druss B, Hartung D, et al. Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second generation antipsychotic drugs. Arch Gen Psychiatry 2010; 67(1): 17–24CrossRef
Metadata
Title
Metabolic and Neurological Complications of Second-Generation Antipsychotic Use in Children
A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Authors
Dr Tamara Pringsheim
Darren Lam
Heidi Ching
Scott Patten
Publication date
01-08-2011
Publisher
Springer International Publishing
Published in
Drug Safety / Issue 8/2011
Print ISSN: 0114-5916
Electronic ISSN: 1179-1942
DOI
https://doi.org/10.2165/11592020-000000000-00000

Other articles of this Issue 8/2011

Drug Safety 8/2011 Go to the issue

Original Research Article

Rates of Spontaneous Reports of Adverse Drug Reactions for Drugs Reported in Children

Review Article

Safety Considerations in Drug Treatment of Depression in HIV-Positive Patients

In Memory

Associate Professor David W.J. Clark 1940–2011

Editorial

Conflicts of Interest in Medicines Safety and Regulation

Review Article

Drug Treatment for Obesity in the Post-Sibutramine Era

Commentary

The Fatal Love of Forms